4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

4D Molecular Therapeutics (FDMT) announced a strategic credit facility agreement with Hercules Capital (HTGC) for up to $200 million in non-dilutive financing. The company drew an initial $20 million at closing, with additional tranches available through 2027 and upon achievement of certain milestones. This financing strengthens 4DMT's cash position of $458 million as of March 31, 2026, and provides operational flexibility as the company advances its lead product 4D-150 through Phase 3 development for wet AMD and DME.